Followers | 9 |
Posts | 729 |
Boards Moderated | 0 |
Alias Born | 05/06/2014 |
Wednesday, November 18, 2020 2:41:02 PM
Except none of them are known to have put any assets in. The recent 8K includes the employment contracts of the two new executives. Schedule IIs show zero stock is owned by either. So they haven't put any of their own cash in.
Baum gets $250K per year, plus bonuses TBD, plus preferred stock TBD.
Piazza gets $225K per year, plus bonuses TBD, plus preferred stock TBD.
Nelson was getting $220K per year.
Other than selling stock, what do you suppose they do with their time? They aren't researchers working in a lab. The Phase 1 FDA trial is done by an independent doctor and hospital, which they don't have anything to do with.
It will be at least 3 years before that Phase 1 trial is completed, then there needs to be a Phase 2, and then a Phase 3 before there is any chance of marketing a product. Assuming no problems with the drug appear in any of the trials.
Given that the drug is a radioisotope, they aren't going to be spending their time setting up a manufacturing facility (i.e., nuclear reactor).
Why are these people involved? Maybe to get over $200K per year for selling a little stock?
By the way, here's a little infographic on Chris Nelson's track record:
But there's a mistake in it. Shareholder loss was 99.7%, not 97%.
Recent QSAM News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/20/2024 10:19:46 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:51:43 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/20/2024 11:09:38 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/16/2024 02:51:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 02:56:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 10:08:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:43:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 08:51:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2023 08:00:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:30:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 10:14:22 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM